The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to United States-based Usona Institute's psilocybin intended for the treatment of major depressive disorder (MDD), it was reported yesterday.
Breakthrough Therapy Designation establishes the FDA's organisational commitment to promoting an efficient development program for psilocybin in MDD.
The new status follows the recent introduction of Usona's Phase two clinical trial, PSIL201, which included around 80 participants at seven study sites around the US. Two of the seven study sites are presently hiring, with the others expected to be active by the first quarter of 2020.
Mirecule expands collaboration with Sanofi to advance FSHD therapy
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Alebund Pharmaceuticals signs licensing and equity agreements with R1 Therapeutics
Apertura Gene Therapy agrees manufacturing collaboration with Viralgen
Humacyte submits Israel MAA for Symvess arterial trauma repair
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
LynxKite Technologies expands Biophytis collaboration
BioDlink named 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Excellence Awards
Vimgreen Pharmaceuticals receives IND clearance for VG081821 in China
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award